Can We “Hedge” against the Development of Antiviral Resistance among Pandemic Influenza Viruses?

article has not abstract

Vyšlo v časopise: Can We “Hedge” against the Development of Antiviral Resistance among Pandemic Influenza Viruses?. PLoS Med 6(6): e32767. doi:10.1371/journal.pmed.1000103
Kategorie: Perspective
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000103

Souhrn

article has not abstract

Zdroje

1. WuJT

LeungGM

LipsitchM

CooperBS

RileyS

2009 Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Med 6 e1000085 doi:10.1371/journal.pmed.1000085

2. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team 2009 Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med Epub ahead of print doi:10.1056/NEJMoa0903810

3. GoossensH

2009 Antibiotic consumption and link to resistance. Clin Microbiol Infect 15 (Suppl 3) 12 15

4. MontoAS

McKimm-BreschkinJL

MackenC

HampsonAW

HayA

2006 Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 50 2395 2402

5. HerlocherML

TrusconR

FentonR

KlimovA

EliasS

2003 Assessment of development of resistance to antivirals in the ferret model of influenza virus infection. J Infect Dis 188 1355 1361

6. DharanNJ

GubarevaLV

MeyerJJ

Okomo-AdhiamboM

McClintonRC

2009 Oseltamivir-Resistance Working Group. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301 1034 1041